Closed Loop Medicine Expands U.S. Patent Portfolio, Advancing AI-Driven Precision Therapies for Cardiometabolic Health
Closed Loop Medicine Ltd., a company focused on AI-enabled precision medicines, continues to expand its U.S. patent portfolio, securing key patents for GLP-1 therapies in obesity and diabetes, as well as direct oral anticoagulants (DOACs) for cardiovascular health.
This strategic milestone, announced on March 24th, strengthens its cardiometabolic treatment portfolio, with over 65 filings across 16 patent families, and reinforces its commitment to delivering precision medicine at scale.
In the growing GLP-1 market, its patents support dose optimization based on patient-specific factors, enabling personalized co-therapies to enhance adherence and outcomes. Additionally, its latest U.S. patent advances AI-powered precision dosing for DOAC therapy, improving safety and efficacy in anticoagulation treatment for stroke prevention and cardiovascular conditions.
Dr. Hakim Yadi OBE, CEO and co-Founder of Closed Loop Medicine, has shared insights on this vision at recent Frontiers Health conferences, in 2023, where he explored how a data-driven approach to dose optimization can improve the effectiveness of treatments, and in 2024, in a fireside chat focused on personalized drug-digital treatments.
DATE: March 24, 2025 | SOURCE: closedloopmedicine.com
Join us and our global community of health innovators in Berlin on November 11-12, 2025.